Get the Stockscreener App
51.86
0.69%
-0.36
After Hours:
51.86
Cytokinetics Inc Stock (CYTK) Latest News
Vestal Point Capital LP Sells 575,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics EVP sells shares worth $366,181 By Investing.com - Investing.com South Africa
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Great Point Partners LLC - MarketBeat
Algert Global LLC Sells 22,738 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics director Wendall Wierenga sells $37,100 in stock By Investing.com - Investing.com Nigeria
Insider Sell Alert: Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics EVP sells shares worth $366,181 - Investing.com
Cytokinetics director Wendall Wierenga sells $37,100 in stock - Investing.com
Intech Investment Management LLC Invests $1.73 Million in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Position Lifted by Massachusetts Financial Services Co. MA - MarketBeat
Westfield Capital Management Co. LP Boosts Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Swiss National Bank Buys 20,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Hypertrophic Cardiomyopathy Pipeline 2024: Clinical Trials - openPR
Cytokinetics price target raised to $103 from $99 at Mizuho - Yahoo Finance
Ontario Teachers Pension Plan Board Purchases New Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan - MSN
Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Cytokinetics (NASDAQ:CYTK) Given New $103.00 Price Target at Mizuho - MarketBeat
Cytokinetics' (CYTK) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Bayer acquires rights to Cytokinetics' heart drug in Japan - MSN
Cytokinetics and Bayer ink deal for aficamten in Japan - The Pharma Letter
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Acquired by Royce & Associates LP - MarketBeat
Cytokinetics CEO Robert Blum sells shares for $252,750 - Investing.com
Cytokinetics CEO Robert Blum sells shares for $252,750 By Investing.com - Investing.com Canada
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HC - GuruFocus.com
Cytokinetics, Bayer in Japan Licensing Pact for Aficamten - MarketWatch
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer - Yahoo Finance
First Turn Management LLC Sells 70,171 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan - Yahoo Finance
Bayer: exclusive licensing agreement with Cytokinetics in Japan - Marketscreener.com
Bayer secures rights to heart drug in multi-million deal - Marketscreener.com
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan - Yahoo Finance
H.C. Wainwright keeps Buy rating on Cytokinetics shares, citing promising data on aficamten and omecamtiv - Investing.com Canada
Cytokinetics' (CYTK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - The Manila Times
Cytokinetics' Aficamten Shows 90% Drop in Heart Surgery Need, Major QoL Gains in HCM Study | CYTK Stock News - StockTitan
Principal Financial Group Inc. Sells 120,497 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 - Marketscreener.com
Significant Portfolio Addition: T. Rowe Price Investment Managem - GuruFocus.com
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com
Cytokinetics: On The Cusp Of Commercialization (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics EVP sells $370,880 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells $370,880 in stock - Investing.com
Cytokinetics' SWOT analysis: cardiac drug maker's stock poised for growth - Investing.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.67 Average Price Target from Brokerages - MarketBeat
FMR LLC Bolsters Stake in Cytokinetics Inc - GuruFocus.com
Cytokinetics to Present at Jefferies London Healthcare Conference 2024 | CYTK Stock News - StockTitan
Lisanti Capital Growth LLC Sells 26,800 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 - Marketscreener.com
Cytokinetics Launches Phase 1 Trial for Novel Muscle Function Drug CK-089 | CYTK Stock News - StockTitan
Abstract 4142906: Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial - AHA Journals
HC Wainwright Forecasts Reduced Earnings for Cytokinetics - MarketBeat
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):